Gagnon Securities Llc decreased Lumber Liquidators Holdings Inc (LL) stake by 30.15% reported in 2017Q3 SEC filing. Gagnon Securities Llc sold 150,010 shares as Lumber Liquidators Holdings Inc (LL)’s stock rose 89.65%. The Gagnon Securities Llc holds 347,558 shares with $13.55 million value, down from 497,568 last quarter. Lumber Liquidators Holdings Inc now has $683.08M valuation. The stock increased 0.63% or $0.15 during the last trading session, reaching $23.98. About 70,739 shares traded. Lumber Liquidators Holdings, Inc. (NYSE:LL) has risen 154.19% since February 20, 2017 and is uptrending. It has outperformed by 137.49% the S&P500.
Analysts expect aTyr Pharma, Inc. (NASDAQ:LIFE) to report $-0.43 EPS on March, 15.They anticipate $0.10 EPS change or 18.87% from last quarter’s $-0.53 EPS. After having $-0.43 EPS previously, aTyr Pharma, Inc.’s analysts see 0.00% EPS growth. The stock increased 1.61% or $0.05 during the last trading session, reaching $3.15. About 85 shares traded. aTyr Pharma, Inc. (NASDAQ:LIFE) has risen 12.96% since February 20, 2017 and is uptrending. It has underperformed by 3.74% the S&P500.
Among 7 analysts covering Life Technologies Corp (NASDAQ:LIFE), 1 have Buy rating, 3 Sell and 3 Hold. Therefore 14% are positive. Life Technologies Corp had 13 analyst reports since August 25, 2015 according to SRatingsIntel. Zacks downgraded the shares of LIFE in report on Tuesday, August 25 to “Hold” rating. Citigroup maintained the shares of LIFE in report on Tuesday, August 16 with “Neutral” rating. As per Wednesday, February 14, the company rating was downgraded by JP Morgan. As per Thursday, September 7, the company rating was initiated by Piper Jaffray. On Wednesday, December 16 the stock rating was initiated by Citigroup with “Neutral”. J.P. Morgan downgraded aTyr Pharma, Inc. (NASDAQ:LIFE) on Wednesday, February 14 to “Sell” rating. The company was downgraded on Wednesday, December 14 by JP Morgan. The firm has “Overweight” rating by JP Morgan given on Thursday, August 11. BMO Capital Markets maintained the stock with “Hold” rating in Wednesday, November 1 report. William Blair downgraded the shares of LIFE in report on Thursday, March 31 to “Market Perform” rating.
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of Physiocrine therapeutics for patients suffering from severe and rare diseases. The company has market cap of $93.74 million. The firm develops Resolaris, which is in Phase Ib/II clinical trials for treating patients with facioscapulohumeral muscular dystrophy , early onset FSHD, and limb-girdle muscular dystrophy, as well as under evaluation to treat Duchenne muscular dystrophy. It currently has negative earnings. The Company’s discovery program includes Stalaris for treating interstitial lung disease with an immune component; and preclinical research program comprises Project ORCA to treat therapeutic applications of Physiocrines.
Among 12 analysts covering Lumber Liquidators Holdings (NYSE:LL), 4 have Buy rating, 1 Sell and 7 Hold. Therefore 33% are positive. Lumber Liquidators Holdings had 28 analyst reports since August 6, 2015 according to SRatingsIntel. The company was maintained on Tuesday, October 31 by Stifel Nicolaus. Piper Jaffray maintained Lumber Liquidators Holdings, Inc. (NYSE:LL) rating on Thursday, September 7. Piper Jaffray has “Hold” rating and $32.0 target. Jefferies maintained it with “Hold” rating and $1900 target in Wednesday, June 14 report. Wedbush downgraded the stock to “Neutral” rating in Monday, February 12 report. The rating was downgraded by Goldman Sachs to “Sell” on Thursday, December 17. The rating was maintained by Piper Jaffray on Tuesday, October 31 with “Hold”. The stock has “Buy” rating by Oppenheimer on Tuesday, August 1. Morgan Stanley maintained the stock with “Equal-Weight” rating in Monday, October 2 report. The firm earned “Outperform” rating on Friday, May 19 by Oppenheimer. The firm earned “Equal Weight” rating on Thursday, August 6 by Stephens.